Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil

Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) -

?

Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and
Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio
Grande do Sul, Brazil, "Multilab") today jointly announced that both
parties have signed an agreement whereby Takeda Farmaceutica Brasil
Ltda. (Sao Paulo, Brazil, "Takeda Brazil"), a wholly-owned subsidiary
of Takeda, aims to acquire Multilab.

Takeda expects that the transaction will be finalized by the end
of 2Q of its fiscal year 2012. Under the agreement, Takeda Brazil
will acquire Multilab in cash for Brazilian Real (BRL) 500 million
upfront and up to BRL 40 million in additional future milestone
payments to the owners of Multilab. Other financial conditions were
not disclosed.

Multilab is a mid-sized pharmaceutical company with annual net
revenues of BRL 140 million in 2011. Its business consists of branded
generics and OTC (over-the-counter) pharmaceutical products. Retail
sales for the company grew in excess of +20% p.a. over the period
2009 - 2011.

Takeda has an established presence in Brazil, manufacturing and
marketing both prescription drugs as well as well-known brands such
as Neosaldina(R) (analgesic), Eparema(R) (digestive) and Nebacetin(R)
(anti-bacterial) comprising its OTC portfolio.

The acquisition of Multilab will position Takeda as one of the top
ten pharmaceutical companies in Brazil(1), enriching its offering to
better cater to the diverse needs of the Brazilian population.
Multilab's leading products include Multigrip(R), the country's
best-selling OTC product for cold and flu treatment in units(2),
which Takeda believes will be an excellent addition to its existing
OTC product line in Brazil.

Multilab has well established distribution through regional
wholesalers and small to mid-sized independent pharmacies, in
particular in emerging regions of the country, which is expected to
complement Takeda's strong relationships with major wholesalers, key
chains and pharmacies in more established cities and state capitals.

"This acquisition significantly reinforces Takeda's position in
Brazil, which is the world's sixth largest economy and the biggest in
South America," said Jostein Davidsen Corporate Officer, Head of
Emerging Markets Commercial Operations for Takeda. "Takeda has
ambitious plans for growth in emerging markets. Brazil is our second
largest emerging market after Russia/CIS in terms of revenues and the
acquisition of Multilab is a clear signal of our intention to become
a significant player both in Brazil and other high-growth markets."

"Multilab will benefit from becoming part of the Takeda group,
enabling the company to reinforce its market position and reach more
patients with its key products in Brazil," said Hilton Cavedon,
Executive Director of Multilab.

Takeda does not expect to revise earnings guidance for its 2012
fiscal year in connection with this acquisition.

Key Strategic Benefits

Takeda expects the acquisition of Multilab will:

- Strengthen Takeda's strategic position in Brazil, 
diversifying its
          portfolio to better meet the needs of the local market, and
the emergence of the
          middle class consumer.
        - Take advantage of Multilab's strong regional distribution 
network and coverage
          of high growth markets in Brazil, such as the Northeast 
region of the country.
        - Allow Takeda to complement its existing OTC portfolio with 
important products,
          such as Multigrip(R), Brazil's best-selling cold and flu 
remedy in units.

1. Acquisition Summary

(1) Acquiring company: Takeda Farmaceutica Brasil Ltda

(2) Owners of Multilab: Mr. Genesio Cervo and Ms Rejane Gobbi

(3) Payment: Cash

(4) Acquisition amount: Brazilian Real 500 million (excl.
conditional/milestone payments)

(5) Planned date of completion: by the end of Q2 FY2012 of Takeda

(6) Financial advisor to Takeda: J.P. Morgan Securities LLC

(7) Legal advisor to Takeda: Mattos Filho Veiga Filho Marrey Jr. e
Quiroga Advogados

(8) Financial advisor to Multilab: BTG Pactual

(9) Legal advisor to Multilab: Pinheiro Neto Advogados

2. Profile of Multilab

(1) Corporate Name: Multilab Industria e Comercio de Produtos
Farmaceuticos Ltda.

(2) Location: Sao Jeronimo/Rio Grande do Sul, Brazil

(3) Representative: Executive Director, Hilton Cavedon

(4) Year of establishment: 1988

(5) Capital stock: 41,750 thousand Brazilian Real

(6) Number of employees: Approximately 650

(7) Relationship with Takeda: No matters to report regarding
capital, personal and transactional relationship between Takeda and
Multilab

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company
with its main focus on pharmaceuticals. As the largest pharmaceutical
company in Japan and one of the global leaders of the industry,
Takeda is committed to striving toward better health for patients
worldwide through leading innovation in medicine. Additional
information about Takeda is available through its corporate website,
http://www.takeda.com.

About Multilab Industria e Comercio de Produtos Farmaceuticos
Ltda.

Founded in 1988, Multilab is among the leading companies of
national capital of the Brazilian pharmaceutical market, with
headquarters in Sao Jeronimo, Rio Grande do Sul. Over the years, it
has been consistently investing in its manufacturing operation, in
people and the expansion of its portfolio, including OTC, RX, Generic
Line and Hospital. For more information, visit the company's
corporate site: http://www.multilab.com.br

1) Combined ranking based on IMS PMB Mar'12 YTD 2)
R05A0 - IMS PMB Mar'12 YTD in Units

Rückfragehinweis:
For all press enquiries please contact: Takeda Pharmaceutical
Company Limited: Public Relations and Investor Relations,
+81-3-3278-2037;
European media, Tobias Cottmann, +41445551510,
[email protected];
Takeda Brazil (Burson Marsteller): Natália Fernandes -
[email protected], Fabiana Delgado - [email protected],
+55-11-3094-2247; Multilab : Gustavo C. Veber, Commercial Director ,
+55-51-3230-4002, [email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print